Patients with type 2 diabetes have an increased demand for pacemaker treatment - a comparison with age- and sex matched controls from the general population.
posted on 2020-09-04, 14:12authored byElina Rautio, Fredrik Gadler, Soffia Gudbjörnsdottir, Stefan Franzén, Lars Rydén, Ann-Marie Svensson, Linda G Mellbin
<b><i>Objective</i></b><i>: </i>Patients
with type 2<i> </i>diabetes mellitus have an increased risk for cardiovascular disease
including arrhythmias. The prevalence of bradyarrhythmia and the subsequent
need for treatment with pacemakers (PM) is less well explored in a contemporary
patient population. The present
study explores 1) whether patients with type 2 diabetes mellitus have an
increased demand for PM implantation compared with an age- and sex-matched
control population without diabetes mellitus; 2) Patient characteristics
associated with increased demand of receiving a PM.
<p><b><i>Methods</i></b><b>:</b>
In this population-matched registry study a total of 416 247 patients with
type 2 diabetes mellitus from the Swedish National Diabetes Registry (NDR) and 2 081
235 age and sex-matched controls selected from the general population were included between 1 January 1998 and 31 December 2012
and followed until 31 December 2013. Mean follow-up time was 7 years. Cox’s
proportional hazard regression analyses were performed to estimate the demand
of PM-treatment and factors identifying patients with such demand.</p>
<p><b><i>Results:</i></b>
Type 2
diabetes mellitus was associated with increased need of PM-treatment (Hazard
ratio (HR) 1.65, 95% CI 1.60-1.69;
p<0.0001) which remained (HR 1.56, 95% CI
1.51-1.60; p<0.0001) after adjustments for age,
sex, educational level, marital status, country of birth and coronary heart
disease. Risk factors for receiving a PM included
increasing age, HbA1c, BMI, diabetes duration, blood pressure- and lipid
lowering medication.</p>
<p><b><i>Conclusion</i></b><i>: </i>The need for PM treatment is higher in patients
with type 2 diabetes than in matched population-based controls. Age, diabetes duration
and HbA1c seem to be risk factors for PM treatment. </p>